EICHOR
● Not Yet Recruiting
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
Condition: Hereditary Hemorrhagic Telangiectasia · Sponsor: Vaderis Therapeutics AG
About this study
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.
This description comes directly from the study's public registry record.
Talk to the study team
Vaderis Therapeutics AG · 844-823-3747 · info@vaderis.com
Always discuss trial participation with your own doctor first.
Locations (0)
| Locations not yet listed on the registry record. |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07743671